As of 14 Oct 2026, Ambrosia Biosciences has raised $100M across 1 verified round on record; latest: $100 million Series B led by Blue Owl Healthcare Opportunities, Deep Track Capital and 1 other, announced 31 Mar 2026.
Small molecule-based therapies for obesity and metabolic disorders, aimed at healthcare providers and patients.
1 source
The release also names an undisclosed institutional investor as a participant. Boulder, Colo. is the dateline, not a stated headquarters.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-03-31 | Blue Owl Healthcare Opportunities, Deep Track Capital, Redmile Group | No recent discussion |
1 source [ VERIFIED ] read against 1 source The release also names an undisclosed institutional investor as a participant. Boulder, Colo. is the dateline, not a stated headquarters. | ||||